Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q2
$1.86M Sell
305,625
-1,230
-0.4% -$7.6K 0.89% 39
2015
Q1
$1.77M Sell
306,855
-1,660
-0.5% -$10.3K 0.84% 39
2014
Q4
$1.92M Sell
308,515
-4,095
-1% -$25.9K 0.91% 39
2014
Q3
$2.05M Sell
312,610
-1,150
-0.4% -$8.1K 1.02% 39
2014
Q2
$2.21M Sell
313,760
-2,225
-0.7% -$16.4K 1.1% 39
2014
Q1
$2.34M Buy
315,985
+2,490
+0.8% +$17.4K 1.23% 36
2013
Q4
$2.3M Buy
+313,495
New +$2.29M 1.23% 35

Other funds holding ABEV

Laidlaw Group's ABEV Position: Q2 2015 in Review

Laidlaw Group reduced its Ambev (ABEV) stake by 0.4% in Q2 2015, selling an estimated $7.6K and leaving 305,625 shares worth $1.86M. The position accounts for 0.89% of the portfolio, ranked #39.

Laidlaw Group first reported a position in ABEV in Q4 2013 and has held it in 7 quarters since. The position peaked at $2.34M in Q1 2014. 302 funds tracked by Wall St. Rank hold ABEV as of Q2 2015.

  • Laidlaw Group held 305,625 shares of Ambev worth $1.86M as of Q2 2015.
  • Laidlaw Group sold 1,230 Ambev shares in Q2 2015, an estimated $7.6K.
  • Ambev made up 0.89% of Laidlaw Group's portfolio in Q2 2015, its #39 holding.
  • Laidlaw Group first reported a position in Ambev in Q4 2013 and has held it in 7 quarters since.
  • Laidlaw Group's Ambev position peaked at $2.34M in Q1 2014.
  • 302 funds tracked by Wall St. Rank held Ambev as of Q2 2015.

Based on Laidlaw Group's 13F filing for Q2 2015, filed 31 Jul 2015.